Shopping Cart
- Remove All
Your shopping cart is currently empty
Razuprotafib (AKB-9778) is a protein tyrosine phosphatase ß (HPTPß) inhibitor with an IC50 of 50 nM. It effectively activates Tie-2 and provides protection against acute kidney injury.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $253 | In Stock | |
| 5 mg | $413 | In Stock | |
| 10 mg | $619 | In Stock | |
| 25 mg | $1,050 | In Stock | |
| 50 mg | $1,370 | In Stock | |
| 100 mg | $1,790 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $533 | In Stock |
| Description | Razuprotafib (AKB-9778) is a protein tyrosine phosphatase ß (HPTPß) inhibitor with an IC50 of 50 nM. It effectively activates Tie-2 and provides protection against acute kidney injury. |
| Targets&IC50 | HPTPß:50 nM |
| In vitro | Razuprotafib inhibits the phosphatase activity of VE-PTP with an IC50 of 17 pM.
Razuprotafib inhibits the phosphatase PTP1B with an IC50 of 780 nM. Razuprotafib inhibits HPTPη (IC50 = 36 pM) . Razuprotafib inhibits HPTPγ (IC50 = 100 pM). Razuprotafib 0.17 to 50 μM HUVEC 10 minutes in WB concentration-dependent phosphorylation of TIE2 and downstream components of the TIE2 signaling pathway, including eNOS, AKT, and ERK. |
| In vivo | Rho-VEGF–transgenic mice s.c. injection 20 mg/kg 12 hours promotes phosphorylation of TIE2 in retinal endothelial cells
Rho-VEGF mice s.c. injection 10-20 mg/kg twice daily for 7 days suppresses subretinal neovascularization. |
| Synonyms | AKB-9778 |
| Molecular Weight | 586.7 |
| Formula | C26H26N4O6S3 |
| Cas No. | 1008510-37-9 |
| Smiles | COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1csc(n1)-c1cccs1 |
| Relative Density. | 1.450 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (170.44 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (6.82 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.